Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 48:330-339, doi:10.1016/j.jacc.2006.03.037 (Published online 22 June 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilkoff, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilkoff, B. L.

A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators

Results From the Prospective Randomized Multicenter EMPIRIC Trial

Bruce L. Wilkoff, MD, FACC*,*, Kevin T. Ousdigian, MS{dagger}, Laurence D. Sterns, MD, FACC{ddagger}, Zengri J. Wang, PhD{dagger}, Ryan D. Wilson, MBA{dagger}, John M. Morgan, MD, FACC§ for the EMPIRIC Trial Investigators

* The Cleveland Clinic Foundation, Cleveland, Ohio
{dagger} Medtronic, Inc., Minneapolis, Minnesota
{ddagger} Victoria Cardiac Arrhythmia Trials, Victoria, British Columbia, Canada
§ Wessex Cardiology, Southampton, England


Figure 1
View larger version (7K):

[in a new window]
 
Figure 1 Programmed implantable cardioverter-defibrillator (ICD) therapies versus heart rate. (A) Percentage of all patients programmed to antitachycardia pacing (ATP) and/or shock therapy (number of patients with ATP or shock therapy on at each heart rate/total number of patients in the arm). The dotted line illustrates that nearly all EMPIRIC arm patients had their ICD enabled to treat tachycardias >150 beats/min. In marked contrast, tailored programming was enabled to treat slower tachycardias in a much smaller proportion of patients. (B) Percent of treated patients programmed to ATP on (number of patients with ATP on at each heart rate/number of patients with ATP or shock therapy on at each heart rate). The dotted line illustrates that nearly all EMPIRIC arm patients had ATP on up to 250 beats/min. In marked contrast, a small proportion of tailored arm patients had ATP on at faster heart rates.

 

Figure 2
View larger version (12K):

[in a new window]
 
Figure 2 Number of episodes by arm. (A) True ventricular tachycardia/ventricular fibrillation (VT/VF) episodes. (B) True supraventricular tachycardia or other non-VT/VF event (SVT) episodes. Solid bars = shocked; ruled bars = not shocked. GEE = general estimating equation adjustment for multiple recurrences per patient.

 

Figure 3
View larger version (16K):

[in a new window]
 
Figure 3 Percentage of episodes shocked—primary end point in the trial. The upper bound for the percentage difference is 1-sided 95% upper confidence bound. SVT = supraventricular tachycardia; other abbreviations as in Figure 2.

 

Figure 4
View larger version (22K):

[in a new window]
 
Figure 4 Time to first shock. (A) All-cause; (B) true VT/VF; (C) true SVT. CI = confidence interval; HR = hazard ratio; other abbreviations as in Figures 2 and 3.

 

Figure 5
View larger version (11K):

[in a new window]
 
Figure 5 Safety and health-care utilization end points. ER = emergency room; other abbreviations as in Figures 2 and 4.

 

Figure 6
View larger version (15K):

[in a new window]
 
Figure 6 Subgroup analysis on time to first all-cause shock. AF = atrial fibrillation; AFL = atrial flutter; AT = atrial tachycardia; CAD = coronary artery disease; EF = ejection fraction; EPS = electrophysiologic study; MVT = monomorphic ventricular tachycardia; other abbreviations as in Figures 1 and 4.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement